2-diethoxyphosphoryl-3-phenylpropionic acid | 86963-66-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-diethoxyphosphoryl-3-phenylpropionic acid
• 英文别名: 2-(diethoxyphosphoryl)-3-phenylpropanoic acid；2-(Diethoxyphosphinyl)-3-phenylpropionic acid；2-Diethoxyphosphoryl-3-phenylpropanoic acid
• CAS: 86963-66-8
• 化学式: C₁₃H₁₉O₅P
• 分子量: 286.265
• InChiKey: MCDHUNFPSOKOHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-diethoxyphosphoryl-3-phenylpropionic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 (1-Chlorocarbonyl-2-phenyl-ethyl)-phosphonic acid diethyl ester
  参考文献：
  名称：

  Synthese de peptides modifies incorporant un motif phosphore n ou c terminal

  摘要：

  A general route to phosphopeptids with a 2-oxoalkylphosphonate moiety at the terminal N-aminogroup or with a 1-aminoalkylphosphonate moiety at the terminal C-carboxyl group is described. The method allows the preparation of various phosphopeptids with an alpha-alkylated carbon atom on the P-C bond from the very available dialkylphosphonoalcanoic acids as starting products.

  DOI：

  10.1016/s0040-4020(01)92278-1
• 作为产物：
  描述：

  ethyl 2-diethylphosphono-3-phenylpropionate 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 以94%的产率得到2-diethoxyphosphoryl-3-phenylpropionic acid
  参考文献：
  名称：

  Krawczyk; Koszuk; Bodalski, Polish Journal of Chemistry, 2000, vol. 74, # 8, p. 1123 - 1128

  摘要：

  DOI：

文献信息

• TRICYCLIC COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1939205A1

  公开（公告）日：2008-07-02

  The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2', R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.

  本发明涉及一种三环化合物，每种化合物由以下式（I）表示：（其中，R1、R2、R2'、R3、R4、X、Y和Z的含义与规范中定义的含义相同）；以及含有该化合物的药物。由于根据本发明的化合物表现出优异的角鲨烯合酶抑制作用和胆固醇合成抑制作用，因此它们可用作哺乳动物（包括人类）的疾病预防和/或治疗药物，例如高脂血症，如高胆固醇血症、高甘油三酯血症、低高密度脂蛋白胆固醇血症和/或动脉粥样硬化。
• Highly Regio- and Enantioselective Hydrogenation of Conjugated α-Substituted Dienoic Acids
  作者：Xian Liu、Song Liu、Quanjun Wang、Gang Zhou、Lin Yao、Qin Ouyang、Ru Jiang、Yu Lan、Weiping Chen

  DOI：10.1021/acs.orglett.0c00915

  日期：2020.4.17

  Highly regio- and enantioselective hydrogenation of conjugated α-substituted dienoic acids was realized for the first time using Trifer–Rh complex, providing a straightforward method for the synthesis of chiral α-substituted γ,δ-unsaturated acids. DFT calculations revealed N+H–O hydrogen bonding interaction is formed to stabilize the transition state and the coordination of 4,5-double bond to Rh(III)

  使用Trifer-Rh配合物首次实现了对共轭α-取代二烯酸的高度区域和对映选择性加氢，为合成手性α-取代的γ，δ-不饱和酸提供了一种简单的方法。DFT计算表明，形成N + H–O氢键相互作用可稳定过渡态，并且4,5-双键与Rh（III）中心的配位将促进还原消除过程。该氢化提供了沙比特利前体的克级合成。
• Pharmaceutical amides, and preparation, formulations and use of thereof
  申请人：The Wellcome Foundation Ltd.

  公开号：US04423242A1

  公开（公告）日：1983-12-27

  Compounds of the general formula ##STR1## wherein Ph is a phenyl group which is optionally substituted by one or more substituents selected from halo (i.e. fluoro, chloro, bromo or iodo), C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, nitro, sulphonyl, aminosulphonyl, trihalomethyl, carboxy, C.sub.1-4 alkoxycarbonyl, amido, C.sub.1-4 alkylamido C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, cyano, aminomethyl or methylsulphonyl; R.sup.a and R.sup.b, which may be the same or different, each represents a hydrogen or alkali metal (e.g. sodium or lithium) atom or a C.sub.1-4 (e.g. ethyl) group; m is 0 or 1; Y is a group of formula: --NH--CH.sub.2 --CO-- or a group of formula: ##STR2## where R.sup.1 is hydrogen or methyl; R.sup.2 is alkyl of 1 to 3 carbon atoms or is methylthiomethyl; and Z is --OR.sup.3 or --NR.sup.4 R.sup.5 where R.sup.3, R.sup.4 and R.sup.5 are each hydrogen or alkyl of 1 to 4 carbon atoms (i.e. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl) and R.sup.3 can further be phenylalkyl having 1 to 3 carbon atoms in the alkylene moiety thereof, or phenyl; and basic salts thereof. These compounds have an advantageous enkephalinase inhibitory activity which renders the compounds useful in medical therapy, e.g. to prolong and/or potentiate in a mammal, the effects of endogenous or exogenous enkephalins. The latter includes synthetic enkepalin analogues.

  通式为##STR1##的化合物，其中Ph是苯基，可以选择性地由卤素（即氟、氯、溴或碘）、C.sub.1-4烷基、氨基、C.sub.1-4烷基氨基、二-C.sub.1-4烷基氨基、硝基、磺酰基、氨基磺酰基、三卤甲基、羧基、C.sub.1-4烷氧基羰基、酰胺基、C.sub.1-4烷基酰胺基、C.sub.1-4烷氧基、C.sub.2-4烯基、氰基、氨甲基或甲基磺酰基取代的苯基；R.sup.a和R.sup.b可以相同也可以不同，分别代表氢或碱金属（例如钠或锂）原子或C.sub.1-4（例如乙基）基团；m为0或1；Y是式：--NH--CH.sub.2 --CO--或式：##STR2## 其中R.sup.1为氢或甲基；R.sup.2为1至3碳原子的烷基或甲基硫代甲基；Z为--OR.sup.3或--NR.sup.4 R.sup.5，其中R.sup.3、R.sup.4和R.sup.5分别为氢或1至4碳原子的烷基（即甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基），并且R.sup.3可以进一步为含有1至3碳原子的烷基的苯基烷基，或苯基；以及其碱性盐。这些化合物具有有利的脑内啡酶抑制活性，使这些化合物在医学治疗中有用，例如在哺乳动物中延长和/或增强内源性或外源性脑内啡酪肽的作用。后者包括合成的脑内啡肽类似物。
• TRICYCLIC COMPOUNDS
  申请人：Sugita Kazuyuki

  公开号：US20090181942A1

  公开（公告）日：2009-07-16

  The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R 1 , R 2 , R 2′ , R 3 , R 4 , X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.

  本发明涉及由以下公式（I）表示的三环化合物（其中，R1，R2，R2'，R3，R4，X，Y和Z的含义如说明书所定义）；以及含有该化合物的药物。由于本发明的化合物表现出优异的角鲨烷合酶抑制作用和胆固醇合成抑制作用，因此它们可用作哺乳动物（包括人类）疾病的预防和/或治疗药物，例如高脂血症、例如高胆固醇血症、高三酰甘油血症和低高密度脂蛋白胆固醇血症和/或动脉硬化。
• Pharmaceutical compounds, and preparation, formulations and use thereof
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0075334A2

  公开（公告）日：1983-03-30

  Compounds of the general formula wheren Ph is a phenyl group which is optionally substituted by one or more substituents selected from halo (i.e. fluoro, chloro, bromo or iodo), C1-4alkyl, amino, C1-4alkylamino, di-C1-4alkylamino, nitro, sulphonyl, aminosulphonyl, trihalomethyl, carboxy, C1-4alkoxycarbonyl, amido, C1-4alky(amido C1-4alkoxy, C2-4alkenyl, cyano, aminomethyl or methylsulphonyl; R' und Rb, which may be the same or different, each represents a hydrogen or alkali metal (eg. sodium or lithium) atom or a C1-4 (eg. ethyl) group; m is 0 or 1; Y is a group of formula: or a group of formula: where R' is hydrogen or methyl; R2 is alkyl of 1 to 3 carbon atoms or is methylthiomethyl; and Z is -OR3 or -NR4Rs where R3, R4 and R5 are each hydrogen or alkyl of 1 to 4 carbon atoms (ie. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl) and R3 can further be phenylalkyl having 1 to 3 carbon atoms in the alkylene moiety thereof, or phenyl; and basic salts thereof. These compounds have an advantageous enkephalinase inhibitor activity which renders the compounds useful in medical therapy, eg. to prolong and/or potentiate in a mammal, the effects of endogenous or exogenous enkephalins. The latter includes synthetic enkephalin analogues.

  通式如下的化合物 其中 Ph 是苯基，可任选被一个或多个取代基取代，这些取代基选自卤代（即C1-4烷基、氨基、C1-4烷基氨基、二-C1-4烷基氨基、硝基、磺酰基、氨磺酰基、三卤甲基、羧基、C1-4烷氧基羰基、氨基、C1-4烷氧基、C2-4烯基、氰基、氨甲基或甲基磺酰基；R'和 Rb 可以相同或不同，各自代表氢原子或碱金属（如钠或锂）原子或 C1-4（如乙烯基）原子。m为 0 或 1； Y 是式中的基团 或式 其中 R' 是氢或甲基； R2 是 1 至 3 个碳原子的烷基或甲硫基；以及 Z是-OR3或-NR4Rs，其中R3、R4和R5各自是氢或1至4个碳原子的烷基（即甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基），R3还可以是在其亚烷基中具有1至3个碳原子的苯基烷基或苯基；以及它们的碱式盐。这些化合物具有良好的脑啡肽酶抑制剂活性，可用于医学治疗，例如延长和/或增强哺乳动物体内的内源性或外源性脑啡肽的作用。后者包括合成的脑啡肽类似物。